TAIPEI MEDICAL UNIVERSITY

Taiwan's Formosa Pharmaceuticals Signs Exclusive Licensing Deal with Almac Discovery for ADC Development

13 days ago

• Taiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with Northern Ireland's Almac Discovery to develop novel antibody-drug conjugates for cancer treatment. • The partnership combines Formosa's antibody expertise with Almac's proprietary drug-linker technology, aiming to address unmet needs in oncology with more targeted therapeutic approaches. • This collaboration represents a significant expansion of Taiwan's growing presence in the global biopharmaceutical sector, particularly in the rapidly evolving ADC market.

Taipei Medical University and MSD Taiwan Forge Landmark Healthcare Innovation Partnership

a month ago

• Taipei Medical University and MSD Taiwan have signed a groundbreaking Memorandum of Understanding to collaborate across six key areas, marking the first large-scale alliance between a global pharmaceutical company and a medical university in Taiwan. • The partnership aims to enhance Taiwan's healthcare ecosystem through initiatives including business mentorship for startups, improved clinical trial capabilities, industry-oriented curricula, and real-world evidence projects. • A cornerstone of the collaboration is the establishment of an "Expedited New Drug Pathway" to streamline access to innovative therapeutics, particularly first-in-class pharmaceuticals tested within TMU's 3,000-bed healthcare system.

Avance Clinical Expands Asia-Pacific Footprint with Four Strategic Partnerships in Taiwan

2 months ago

• Avance Clinical, a global Contract Research Organization, has signed Memorandums of Understanding with four premier Taiwanese medical institutions, strengthening its GlobalReady model for biotech companies. • The partnerships with Taichung Veterans General Hospital, Taipei Medical University, China Medical University Hospital, and Kaohsiung Medical University Chung-Ho Memorial Hospital provide US biotechs access to Taiwan's advanced healthcare infrastructure and diverse patient populations. • This strategic expansion leverages Taiwan's regulatory efficiency and clinical expertise, particularly in areas like CAR-T cell immunotherapy, to accelerate innovative treatment development for patients worldwide.

Cost Barriers Lead to Medication Non-Adherence in 17.8% of US Asthma Patients, Study Reveals

5 months ago

• A comprehensive analysis of National Health Interview Survey data reveals approximately 2.99 million US adults with asthma report cost-related medication non-adherence, despite declining trends over the past decade. • Patients experiencing cost-related non-adherence face significantly higher risks of asthma attacks (95% higher) and emergency room visits (63% higher) compared to adherent patients. • Demographics play a crucial role, with non-Hispanic Black patients (20.3%) and females (19.5%) showing higher rates of cost-related non-adherence, while adults over 60 demonstrate better medication adherence.

Ainos Receives IRB Approval for Sjogren's Syndrome Clinical Study

6 months ago

• Ainos has secured Institutional Review Board (IRB) approval to proceed with a clinical study focused on Sjogren's Syndrome. • The study aims to evaluate a novel therapeutic approach for managing the symptoms and progression of Sjogren's Syndrome. • This approval marks a significant step forward for Ainos in expanding its research and development efforts in autoimmune diseases.

Ainos Receives IRB Approval to Study VELDONA® for Sjögren's Syndrome

6 months ago

• Ainos, Inc. has received IRB approval from Shuang Ho Hospital in Taiwan for a clinical trial of VELDONA® in treating Sjögren's syndrome. • The open-label study aims to evaluate VELDONA®'s efficacy in improving salivary flow and alleviating dryness symptoms in 24 patients over 24-48 weeks. • The trial's secondary endpoints include assessing improvements in dryness symptoms, disease activity, and salivary gland function via imaging. • Ainos anticipates completing all regulatory approvals by Q1 2025, with patient recruitment expected to begin in May 2025.

Ainos and Taiwan Tanabe Partner to Advance VELDONA® for Sjögren's Syndrome

6 months ago

• Ainos partners with Taiwan Tanabe Seiyaku to manufacture and promote VELDONA®, a low-dose interferon alpha formulation, for Sjögren's disease in Taiwan. • Ainos received IRB approval from Shuang Ho Hospital for a clinical trial evaluating VELDONA®'s efficacy in improving salivary flow and alleviating dryness symptoms. • The open-label trial will enroll 24 patients with primary Sjögren's, administering sublingual VELDONA® tablets over 24-48 weeks, with completion expected by December 2026.

Oneness Biotech's SNS812 Demonstrates Superior Efficacy Against COVID-19 Variants in Phase 2 Trial

8 months ago

• Oneness Biotech and Microbio (Shanghai)'s SNS812 achieved statistically significant and clinically meaningful endpoints in a Phase 2 trial for COVID-19 treatment. • SNS812 demonstrated efficacy against prevalent COVID-19 variants, including JN.1, KP1-4, LB.1, BA.2, and XBB, with a good safety profile and no drug-related adverse events. • The trial showed SNS812 significantly reduced the time to viral negativity (median 2.9 days in the 200mg group) and improved symptoms like loss of smell and taste compared to placebo. • SNS812 presents a potential breakthrough solution for treating COVID-19, addressing the urgent need for therapies effective against emerging variants.